본문 바로가기
KERD
논문KCI 등재

Follicular lymphoma: updates for pathologists

Khanlari Mahsa|Jennifer R. Chapman
대한병리학회|2022.01|Journal of Pathology and Translational Medicine|제56권 제1호|pp. 1-15|DOI 10.4132/jptm.2021.09.29

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

TreatmentImmunohistochemistryPrognosisMolecularCytogeneticsFollicular lymphoma
주제분류병리학

초록

Follicular lymphoma (FL) is the most common indolent B-cell lymphoma and originates from germinal center B-cells (centrocytes and centroblasts) of the lymphoid follicle. Tumorigenesis is believed to initiate early in precursor B-cells in the bone marrow (BM) that acquire the t(14;18)(q32;q21). These cells later migrate to lymph nodes to continue their maturation through the germinal center reaction, at which time they acquire additional genetic and epigeneticabnormalities that promote lymphomagenesis. FLs are heterogeneous in terms of their clinicopathologic features. Most FLs are indolent and clinically characterized by peripheral lymphadenopathy with involvement of the spleen, BM, and peripheral blood in a substantial subset of patients, sometimes accompanied by constitutional symptoms and laboratory abnormalities. Diagnosis is established by the histopathologic identification of a B-cell proliferation usually distributed in an at least partially follicular pattern, typically, but not always, in a lymph node biopsy. The B-cell proliferation is biologically of germinal center cell origin, thus shows an expression of germinal center-associated antigens as detected by immunophenotyping. Although many cases of FLs are typical and histopathologic features are straightforward, the biologic and histopathologic variability of FL is wide, and an accurate diagnosis of FL over this disease spectrum requires knowledge of morphologic variants that can mimic other lymphomas, and rarely non-hematologic malignancies, clinically unique variants, and pitfalls in the interpretation of ancillary studies. The overall survival for most patients is prolonged, but relapses are frequent. The treatment landscape in FL now includes the application of immunotherapy and targeted therapy in addition to chemotherapy.

Abstract

Follicular lymphoma (FL) is the most common indolent B-cell lymphoma and originates from germinal center B-cells (centrocytes and centroblasts) of the lymphoid follicle. Tumorigenesis is believed to initiate early in precursor B-cells in the bone marrow (BM) that acquire the t(14;18)(q32;q21). These cells later migrate to lymph nodes to continue their maturation through the germinal center reaction, at which time they acquire additional genetic and epigeneticabnormalities that promote lymphomagenesis. FLs are heterogeneous in terms of their clinicopathologic features. Most FLs are indolent and clinically characterized by peripheral lymphadenopathy with involvement of the spleen, BM, and peripheral blood in a substantial subset of patients, sometimes accompanied by constitutional symptoms and laboratory abnormalities. Diagnosis is established by the histopathologic identification of a B-cell proliferation usually distributed in an at least partially follicular pattern, typically, but not always, in a lymph node biopsy. The B-cell proliferation is biologically of germinal center cell origin, thus shows an expression of germinal center-associated antigens as detected by immunophenotyping. Although many cases of FLs are typical and histopathologic features are straightforward, the biologic and histopathologic variability of FL is wide, and an accurate diagnosis of FL over this disease spectrum requires knowledge of morphologic variants that can mimic other lymphomas, and rarely non-hematologic malignancies, clinically unique variants, and pitfalls in the interpretation of ancillary studies. The overall survival for most patients is prolonged, but relapses are frequent. The treatment landscape in FL now includes the application of immunotherapy and targeted therapy in addition to chemotherapy.

참고문헌 (94)

  1. Jaffe ES, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.266~277 (2017), IARC Press
  2. Brill NE, "Generalized giant lymph follicle hyperplasia of lymph nodes and spleen; a hitherto undescribed type", Am J Med, 13, pp.570~574 (1952)
  3. Lukes RJ, "The pathology and nomenclature of Hodgkin's disease", Cancer Res, 26, pp.1063~1083 (1966)
  4. Lennert K, "History of the European Association for Haematopathology" (2006), Springer
  5. Harris NL, "A revised European-American classification of lymphoid neoplasms : a proposal from the International Lymphoma Study Group", Blood, 84, pp.1361~1392 (1994)
  6. Anderson JR, "Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project", Ann Oncol, 9, pp.717~720 (1998)
  7. "A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project", Blood, 89, pp.3909~3918 (1997)
  8. Roulland S, "Early steps of follicular lymphoma pathogenesis", Adv Immunol, 111, pp.1~46 (2011)
  9. Sungalee S, "Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression", J Clin Invest, 124, pp.5337~5351 (2014)
  10. Carbone A, "Follicular lymphoma", Nat Rev Dis Primers, 5, pp.83~ (2019)
  11. Green MR, "Chromatin modifying gene mutations in follicular lymphoma", Blood, 131, pp.595~604 (2018)
  12. Green MR, "Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation", Proc Natl Acad Sci U S A, 112, pp.E1116~E1125 (2015)
  13. Green MR, "Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma", Blood, 121, pp.1604~1611 (2013)
  14. Mamessier E, "Nature and importance of follicular lymphoma precursors", Haematologica, 99, pp.802~810 (2014)
  15. Goldin LR, "Highly increased familial risks for specific lymphoma subtypes", Br J Haematol, 146, pp.91~94 (2009)
  16. Skibola CF, "Genetic variants at 6p21.33are associated with susceptibility to follicular lymphoma", Nat Genet, 41, pp.873~875 (2009)
  17. Smith S, "Transformed lymphoma : what should I do now?", Hematology Am Soc Hematol Educ Program, 2020, pp.306~311 (2020)
  18. Trecourt A, "Plasticity of mature B cells between follicular and classic Hodgkin lymphomas : a series of 22 cases expanding the spectrum of transdifferentiation", Am J Surg Pathol, 46, pp.58~70 (2022)
  19. Sarkozy C, "Peripheral blood involvement in patients with follicular lymphoma : a rare disease manifestation associated with poor prognosis", Br J Haematol, 164, pp.659~667 (2014)
  20. 유창훈, "Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor", Blood Research, 49(3), pp.148~153 (2014), 대한혈액학회
  21. Bain BJ, "Diagnosis of follicular lymphoma from the peripheral blood", Am J Hematol, 93, pp.1111~1112 (2018)
  22. Medeiros LJ, "AFIP atlas of tumor pathology, series 4. Tumors of the lymph nodes and spleen. Follicular lymphoma" (2017), American Registry of Pathology
  23. Pina-Oviedo S, "Follicular lymphoma with hyaline-vascular Castleman-like features : analysis of 6 cases and review of the literature", Hum Pathol, 68, pp.136~146 (2017)
  24. Kojima M, "Histological variety of floral variant of follicular lymphoma", APMIS, 114, pp.626~632 (2006)
  25. Osborne BM, "Follicular lymphoma mimicking progressive transformation of germinal centers", Am J Clin Pathol, 88, pp.264~269 (1987)
  26. Coffing BN, "Signet ring cell lymphoma in a patient with elevated CA-125", J Clin Oncol, 29, pp.e416~e418 (2011)
  27. Cong P, "In situ localization of follicular lymphoma : description and analysis by laser capture microdissection", Blood, 99, pp.3376~3382 (2002)
  28. Jegalian AG, "Follicular lymphoma in situ : clinical implications and comparisons with partial involvement by follicular lymphoma", Blood, 118, pp.2976~2984 (2011)
  29. Vogelsberg A, "Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype", Haematologica, 106, pp.2673~2681 (2021)
  30. Schmidt J, "Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma", Leukemia, 28, pp.1103~1112 (2014)
  31. Kosmidis P, "Next generation sequencing of the clonal IGH rearrangement detects ongoing mutations and interfollicular trafficking in in situ follicular neoplasia", PLoS One, 12, pp.e0178503~ (2017)
  32. Adam P, "Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage", Am J Surg Pathol, 29, pp.1661~1664 (2005)
  33. Marks E, "Duodenal-type follicular lymphoma : a clinicopathologic review", Arch Pathol Lab Med, 142, pp.542~547 (2018)
  34. Hellmuth JC, "Duodenaltype and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles", Blood, 132, pp.1695~1702 (2018)
  35. Sato Y, "Duodenal follicular lymphomas share common characteristics with mucosa-associated lymphoid tissue lymphomas", J Clin Pathol, 61, pp.377~381 (2008)
  36. Katzenberger T, "A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36", Blood, 113, pp.1053~1061 (2009)
  37. Siddiqi IN, "Characterization of a variant of t(14;18)negative nodal diffuse follicular lymphoma with CD23 expression, 1p36", TNFRSF14 abnormalities, and STAT6 mutations, 2016, pp.29, 570~581
  38. Finn LS, "Primary follicular lymphoma of the testis in childhood", Cancer, 85, pp.1626~1635 (1999)
  39. Sovani V, "Bone marrow trephine biopsy involvement by lymphoma : review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings", J Clin Pathol, 67, pp.389~395 (2014)
  40. Torlakovic E, "Follicular pattern of bone marrow involvement by follicular lymphoma", Am J Clin Pathol, 118, pp.780~786 (2002)
  41. Mollejo M, "Splenic follicular lymphoma : clinicopathologic characteristics of a series of 32 cases", Am J Surg Pathol, 33, pp.730~738 (2009)
  42. Howard MT, "Follicular lymphoma of the spleen : multiparameter analysis of 16 cases", Am J Clin Pathol, 131, pp.656~662 (2009)
  43. Ferry JA, "Hematopathology", pp.321~352 (2017), Elsevier
  44. Menter T, "Diagnostic uility of the germinal center-associated markers GCET1, HGAL, and LMO2 in hematolymphoid neoplasms", Appl Immunohistochem Mol Morphol, 23, pp.491~498 (2015)
  45. Pittaluga S, "BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin’s lymphomas", J Pathol, 179, pp.145~150 (1996)
  46. Marafioti T, "Another look at follicular lymphoma : immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups", Histopathology, 62, pp.860~875 (2013)
  47. Bosga-Bouwer AG, "Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations : t(14;18)and 3q27 are mutually exclusive", Blood, 101, pp.1149~1154 (2003)
  48. Guo Y, "Low-grade follicular lymphoma with t(14;18)presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances", Leukemia, 19, pp.1058~1063 (2005)
  49. Nann D, "Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease", Blood Adv, 4, pp.5652~5665 (2020)
  50. Kendrick SL, "BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma", Hum Pathol, 45, pp.2144~2153 (2014)
  51. Lai R, "Frequency of CD43 expression in non-Hodgkin lymphoma : a survey of 742 cases and further characterization of rare CD43+ follicular lymphomas", Am J Clin Pathol, 111, pp.488~494 (1999)
  52. Tiesinga JJ, "CD5+ follicle center lymphoma. Immunophenotyping detects a unique subset of “floral” follicular lymphoma", Am J Clin Pathol, 114, pp.912~921 (2000)
  53. Chang KC, "Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma", J Pathol, 201, pp.404~412 (2003)
  54. Wang SA, "Low histologic grade follicular lymphoma with high proliferation index : morphologic and clinical features", Am J Surg Pathol, 29, pp.1490~1496 (2005)
  55. Hoglund M, "Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas", Genes Chromosomes Cancer, 39, pp.195~204 (2004)
  56. Espinet B, "FISH is better than BIOMED-2PCR to detect IgH", BCL2 translocation in follicular lymphoma at diagnosis using paraffin-embedded tissue sections, 2008, pp.32, 737~742
  57. Leich E, "Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus", Leukemia, 30, pp.854~860 (2016)
  58. Chaudhary S, "Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma", Hum Pathol, 114, pp.19~27 (2021)
  59. Bisso A, "MYC in germinal center-derived lymphomas : mechanisms and therapeutic opportunities", Immunol Rev, 288, pp.178~197 (2019)
  60. Pasqualucci L, "Genetics of follicular lymphoma transformation", Cell Rep, 6, pp.130~140 (2014)
  61. Huet S, "A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma : a retrospective training and validation analysis in three international cohorts", Lancet Oncol, 19, pp.549~561 (2018)
  62. Elenitoba-Johnson KS, "Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma", Blood, 91, pp.4677~4685 (1998)
  63. Bouska A, "Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma", Blood, 123, pp.1681~1690 (2014)
  64. Evans PA, "Significantly improved PCRbased clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936", Leukemia, 21, pp.207~214 (2007)
  65. Bagg A, "Immunoglobulin heavy chain gene analysis in lymphomas : a multi-center study demonstrating the heterogeneity of performance of polymerase chain reaction assays", J Mol Diagn, 4, pp.81~89 (2002)
  66. Weiss LM, "Benign lymphadenopathies", Mod Pathol, 26(Suppl 1), pp.S88~S96 (2013)
  67. Mantei K, "Flow cytometric evaluation of CD38 expression assists in distinguishing follicular hyperplasia from follicular lymphoma", Cytometry B Clin Cytom, 76, pp.315~320 (2009)
  68. Seegmiller AC, "The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms", Cytometry B Clin Cytom, 96, pp.20~29 (2019)
  69. Khanlari M, "CD45-negative follicular lymphoma : a rare diagnostic pitfall of a common entity", Cytometry B Clin Cytom, 100, pp.406~408 (2021)
  70. Younes S, "Pitfalls in the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma: variant patterns, borderlines and mimics", Cancers (Basel), 13, pp.3021~ (2021)
  71. Poveda J, "Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma", Leuk Lymphoma, 62, pp.1116~1122 (2021)
  72. Wang Z, "IRTA1 and MNDA expression in marginal zone lymphoma: utility in differential diagnosis and implications for classification", Am J Clin Pathol, 151, pp.337~343 (2019)
  73. Link BK, "Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States : data from the observational National LymphoCare Study", Br J Haematol, 184, pp.660~663 (2019)
  74. Casulo C, "Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death : an analysis from the National LymphoCare Study", J Clin Oncol, 33, pp.2516~2522 (2015)
  75. Sarkozy C, "Cause of death in follicular lymphoma in the first decade of the rituximab era : a pooled analysis of French and US cohorts", J Clin Oncol, 37, pp.144~152 (2019)
  76. Kridel R, "Histological transformation and progression in follicular lymphoma : a clonal evolution study", PLoS Med, 13, pp.e1002197~ (2016)
  77. Lee AY, "Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B", J Clin Oncol, 15, pp.1745~1753 (1997)
  78. Solal-Celigny P, "Follicular lymphoma international prognostic index", Blood, 104, pp.1258~1265 (2004)
  79. Federico M, "Follicular lymphoma international prognostic index 2 : a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project", J Clin Oncol, 27, pp.4555~4562 (2009)
  80. Pastore A, "Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma : a retrospective analysis of a prospective clinical trial and validation in a population-based registry", Lancet Oncol, 16, pp.1111~1122 (2015)
  81. Wahlin BE, "Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505patients with long follow-up times", Br J Haematol, 156, pp.225~233 (2012)
  82. Ross CW, "Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis", Clin Cancer Res, 13, pp.4777~4785 (2007)
  83. Khanlari M, "Concurrent TP53 mutation and deletion in refractory low-grade follicular lymphoma", Clin Lymphoma Myeloma Leuk, 21, pp.e626~e629 (2021)
  84. Ollila TA, "Chemotherapy-free management of follicular and marginal zone lymphoma", Cancer Manag Res, 13, pp.3935~3952 (2021)
  85. Schuster SJ, "Bispecific antibodies for the treatment of lymphomas : promises and challenges", Hematol Oncol, 39(Suppl 1), pp.113~116 (2021)
  86. Mondello P, "Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A : evidence from a multicenter, retrospective study", Oncologist, 23, pp.454~460 (2018)
  87. Dreyling M, "Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma", Ann Oncol, 28, pp.2169~2178 (2017)
  88. Pagel JM, "Refining the management of relapsed or refractory follicular lymphoma : case scenarios", Clin Adv Hematol Oncol, 18(Suppl 20), pp.20~21 (2020)
  89. Pongas G, "Recent advances in the management of patients with relapsed", refractory follicular lymphoma, 2021, pp.11, 55~66
  90. Italiano A, "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours : a first-in-human, open-label, phase 1 study", Lancet Oncol, 19, pp.649~659 (2018)
  91. Evens AM, "A phase I", II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed, Clin Cancer Res, pp.2016, 22[DOI]
  92. Ribrag V, "Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study", Haematologica, 102, pp.903~909 (2017)
  93. Sawalha Y, "Profile of polatuzumab vedotin in the treatment of patients with relapsed", refractory non-Hodgkin Lymphoma : a brief report on the emerging clinical data, 2020, pp.13, 5123~5133
  94. Advani R, "CD47 blockade by Hu5F9-G4and rituximab in non-Hodgkin’s lymphoma", N Engl J Med, 379, pp.1711~1721 (2018)

관련 논문AI추천

Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advancesRobert Kridel대한내과학회 · The Korean Journal of Internal Medicine2025 · 제40권 제3호Classical Hodgkin lymphoma following follicular lymphoma: a case report김보미영남대학교 의과대학 · Journal of Yeungnam Medical Science2023 · 제40권 제1호Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives고영혜, 김영아, 김지은, 김현정, 백진호, 신봉경, 윤선옥, 전윤경, 차희정, 허주령대한병리학회 · Journal of Pathology and Translational Medicine2017 · 제51권 제3호Morphologic variant of follicular lymphoma reminiscent of hyaline-vascular Castleman disease고지원, 전윤경대한병리학회 · Journal of Pathology and Translational Medicine2020 · 제54권 제3호Smad1 Expression in Follicular Lymphoma고재향대한병리학회 · Journal of Pathology and Translational Medicine2015 · 제49권 제3호Composite follicular lymphoma and classic Hodgkin lymphoma고영혜, 김대식, 김한나, 유은상, 전민지, 최철원대한병리학회 · Journal of Pathology and Translational Medicine2022 · 제56권 제1호

이 간행물의 다른 논문 (7건)

Clinicopathological differences in radiation-induced organizing hematomas of the brain based on type of radiation treatment and primary lesions박미나, 김명선, 차윤진, 장종희, 김세훈pp. 16-21Association of PTTG1 expression with invasiveness of non-functioning pituitary adenomas이혜원, 박형식, 김순구, 김상표, 황일선, 금수정pp. 22-31Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma백진호, 권현정, 고지원, 이기림, 전윤경, 이정옥pp. 32-39Polo-like kinase 4 as a potential predictive biomarker of chemoradioresistance in locally advanced rectal cancer김신, 황일선, 변상준, 오현승, 권선영, 이혜원, 이재호, 김순구, 배성욱pp. 40-47Chronic lymphocytic leukemia and concurrent seminoma in the same testisKosuke Miyai, Fumihisa Kumazawa, Kimiya Sato, Hitoshi Tsudapp. 48-52
원문 보기